Vol. 2 No. 8 (2022)
Reimbursement Recommendations

Sodium Phenylbutyrate and Ursodoxicoltaurine (Albrioza)

Published August 8, 2022

Key Messages

  • CADTH recommends that Albrioza be reimbursed by public drug plans for the treatment of patients with amyotrophic lateral sclerosis (ALS) if certain conditions are met.
  • Albrioza should only be covered to treat those who have a diagnosis of definite ALS, have had symptoms for 18 months or less, have a forced vital capacity (FVC) of at least 60% of predicted, and do not require permanent noninvasive or invasive breathing support.
  • Albrioza should only be reimbursed if prescribed by a specialist with experience diagnosing and managing ALS and if the cost is reduced.